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In 2004 the International Life Sciences Institute (ILSI) Risk Science Institute established an expert working
group to assess the lessons learned from the implementation of standardized tests for developmental
neurotoxicity in experimental animals. This introduction summarizes the working group process and the four
reports from the expert working group addressing: the use of positive controls, understanding variability,
appropriate statistical techniques, and interpretation. The reports address the 1991 US Environmental
Protection Agency standardized protocol for evaluation of developmental neurotoxicity (DNT) and the 2007
Organisation for Economic Co-operation and Development (OECD) Test Guidelines for DNT. The EPA protocol
is comprised of tests for evidence of deficits in neurobehavioral function, including auditory startle
habituation, motor activity, associative learning and memory, and neuropathologic examination, including
simple morphometric analysis.
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Approximately 12 million children in the United States are afflicted
with a learning, developmental, or behavioral disability including
neurodevelopmental disorders, such as autism, attention-deficit
hyperactivity disorder, and mental retardation. The incidence of new
cases of neurodevelopmental disorders appears to be increasing [1–3].
This may be due to better diagnostic techniques by pediatricians and
other health care providers or may be related to changes in environ-
mental exposures to neurodevelopmental toxins, or possibly both of
these factors. Improved understanding of the neurotoxic effects of
potentially toxic substances in the environment has become a public
health and societal priority worldwide.
In 2004with the support of United States Environmental Protection
Agency (US EPA), the International Life Sciences Institute (ILSI)
Research Foundation/Risk Science Institute established an interna-
tional expert working group on neurodevelopmental endpoints
consisting of scientists possessing technical expertise from the
governmental, academic, industrial, and public interest sectors. The
group was charged with assessing the lessons learned from the
implementation of the US EPA developmental neurotoxicity guideline.
Table 1 presents themembers of the expert working group. The expert
working group met three times over a period of two years and
developed the four reports presented in this edition of the journal. The
reports evaluating the use of positive controls, addressing variability in
data, use of appropriate statistical techniques, and interpretation of
treatment-related effects comprise a consensus of the expertise of the
work group members.
Developmental neurotoxicity (DNT) refers to any adverse effect of
exposure to a toxic substance on the normal development of nervous
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system structures and/or functions. Testing for developmental neuro-
toxicity involves functional and neuropathological assessments in
experimental animal offspring during and following maternal expo-
sure. To be most useful, animal studies must have high predictive
value, both positive and negative. This means that they must include
endpoints that can predict that an agent will either be neurotoxic in
humans or not. Additionally, it is important that the tests be suffi-
ciently sensitive so as to detect effects of positive agents at exposures
relevant to those experience by humans.
In 1991, the US EPA issued a guideline for DNT evaluation and in
2007 the Organisation for Economic Co-operation and Development
(OECD) finalized OECD Testing Guidelines for DNT [4,5]. The US EPA
protocol recommends prenatal and perinatal exposure followed by
pre- and post-weaning tests for evidence of deficits in neurobeha-
vioral function, including auditory startle habituation, motor activity,
associative learning and memory, and neuropathologic examination,
including simple morphometric analysis.
The following is a summary of the four reports included in this
issue, which when taken together, offer a review of findings from
the US EPA testing paradigm for DNT testing and provide many
recommendations that should enhance our ability to conduct and
interpret these types of tests in the future.
1. Undertaking positive control studies as part of developmental
neurotoxicity testing
Positive controls are “reference standards” that serve multiple
purposes. Positive control data are instrumental in evaluating labo-
ratory proficiency in detecting chemical-induced changes in mea-
sured endpoints. Positive control data are valuable in a weight-of-
evidence approach to help determine the biological significance of
results and to provide confidence in negative results fromDNTstudies.
The positive control data should be derived from studies that were
performed in the same laboratory within the past few years, utilizing
(to the greatest extent possible) the staff and equipment that will be
used in conducting the studies of interest [6]. Positive control data
should demonstrate the sensitivity of the procedures used and the
competence of the laboratory in the evaluation of effects in postnatal
animals pre- or perinatally exposed to chemicals, in addition to esta-
blishing test norms for all critical endpoints. This report provides a
practical guide for the use and interpretation of positive control
studies in DNT tests, including suggestions for test substances that can
be used as positive controls at the different endpoints.
2. Determining normal variability in a developmental
neurotoxicity test
When evaluating the results of any toxicity study, it is necessary to
understand the normal variability that is observed in the parameters
being measured so that an evaluation can be made of whether the
findings are within the normal range or outside this range. A number
of intrinsic and extrinsic factors can contribute to the variability
within or between subjects in DNT studies. Sources of variability
include factors related to environmental conditions, personnel,
experimental procedures and instrumentation. Controlling variability
to the extent possible in the experiment is necessary to provide sound
data for regulatory and risk assessment evaluations. This report presents
a framework for investigators and regulators to use in comparing
achieved versus expected levels of variability in DNT study data.
Elements of the framework include: characterization of variability in
the dataset; identification of appropriate datasets for comparison;
evaluationof similarities and differences in variability betweendatasets,
and examination of possible sources of the variability, including those
related to test conduct and test design.
3. Statistical issues and techniques appropriate for developmental
neurotoxicity testing
Appropriate statistical analyses of the behavioral data collected in
DNT studies are imperative, including attention to within-litter
correlations, gender and repeated testing as factors, and approaches
specific for the different data types. This report presents an exami-
nation of the statistical approaches currently being used in DNT
testing with recommendations for improving data analysis and re-
porting. Critical to the success of the analysis is specifying the planned
statistical analyses a priori. A survey of current statistical practices
from six testing laboratories revealed a range of flawed procedures.
The major deficiencies that were routinely observed revolved around:
Type I and II error considerations; litter allocation and analysis; ana-
lysis using sex as a factor; analysis using repeated measures; and
statistical analysis assumptions.
4. Identification and interpretation of developmental
neurotoxicity effects
The reliable detection, measurement, and interpretation of treat-
ment-related developmental neurotoxicity (DNT) effects depends on
appropriate study design and execution, using scientifically estab-
lished methods, with appropriate controls to minimize confounding
factors. Appropriate statistical approaches should be optimized for the
specific endpoints in advance, analyzing effects across time and func-
tional domains as far as possible. If available, biomarkers of exposure
are useful to assess the bioavailability of toxicants to the dam and
offspring in utero and after birth. Finally, “weight of evidence”
principles are used to aid assessment of the biological significance of
differences from concurrent controls. These effects should be inter-
preted in light of available information from historical controls,
positive controls, maternal and offspring systemic toxicity, and other
relevant toxicological data. This report provides a framework for the
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integration of all these types of information in the interpretation of
DNT studies.
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